BREVITEST TECHNOLOGIES is developing a biomedical immunoassay platform technology that could allow consumers, patients, caregivers, and others to more easily detect and quantify molecules of interest from a variety of sample types like blood, saliva, urine and water. This is a compact, portable, point-of-care device that is sensitive, specific and rapid. This is a broadly applicable platform technology targeted towards markets with an unmet need for a sensitive, easy to use, point of care method to quantify molecules. Potential markets include physician’s office laboratories for immediate testing of disease markers like PSA or TSH, hospitals for bedside testing, drug titration and emergency diagnostics in the ER, veterinary testing, population screening for endemic diseases or outbreaks, and consumer health testing for home health or lifestyle applications.
This platform technology can test for a variety of analytes, including proteins, small molecules, and serum antibodies (serology). It is accurate, rapid (runtime of less than 15 minutes, portable (less than 6” in any dimension), economical (cost per test to be significantly lower than reimbursement levels), user-friendly (one-step completely automated testing), complete system (analyzer performs entire ELISA, including optical reading and data upload to cloud with no additional equipment needed), and secure (data accessible only to indivuduals with appropriate permissions).
Contact us for more information.